Introduction: Stem cells based therapies are the most promising and powerful method to provide patients specific tissue substitutes for the regeneration or reconstruction of tissue and organs.

Aim: Using bone marrow stimulation for maxillofacial bone reconstruction surgery.

Design: We have developed and original process to awake the bone marrow in humans, the last being considered as a physiological bioreactor to produce autologous stem cells.

Patient and method: We injected a combination of autologous platelet rich-plasma solution added with recombinant human soluble tissue factor (Rhstf) in the posterior eliac crest. Applied on 13 patients.

Results: Our trial showed the feasibility and harmless of the procedure. Whereas no modification of stem cell phenotype was noticed, an increase of medullar cellularity was observed on the day 3 after injection. Endothelial progenitor cells (EPC) were mobilized to the bloodstream without stimulation of hematopoietic stem cells (HSC). Mesenchymal stem cells (Msc) count in bone marrow increased with a specific commitment to preosteoblastic cell population both in vivo and in vitro.

Conclusion: Human bone marrow can be safety used as a bioreactors for focused stem cells production.

Conflict of interest: None declared.